NICE re-evaluates osteoporosis guidance

NICE is to release its economic model to consultees as it re-evaluates guidance on the primary and secondary prevention of fragility fractures in postmenopausal women, following a successful judicial review by pharmaceutical company Servier.

Mr Justice Holman set out a full process for the re-evaluation of the guidance.

However, the guidance will remain in place until the re-evaluation has been completed.

Servier Laboratories had taken NICE to the High Court because it believed that its osteoporosis guidance was unfairly and unnecessarily restricting access to Protelos (strontium ranelate) for many patients who could benefit from the drug.

Currently, NICE guidance could leave up to 15% of women with osteoporosis, who cannot tolerate bisphosphonates, at risk of developing fractures.

Dr Tim Spector, consultant rheumatologist at St Thomas’ Hospital, London, said: ‘I am disappointed that Justice Holman has ruled that the NICE guidance on osteoporosis will not be quashed pending its re-evaluation.

‘I am, however, confident healthcare professionals will exercise their professional judgement and ensure the best possible care for their patients.’

  • Do you think NICE should be more open?

Comment below and tell us what you think

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins


Already registered?

Sign in